Drug
Monalizumab clinical trials
Also written IPH2201.
Keep track of what changes. Save the monalizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 11
AstraZeneca (3) · Innate Pharma (3) · Assistance Publique Hopitaux De Marseille (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · National Cancer Institute (NCI) (1) · The Netherlands Cancer Institute (1) · MedImmune LLC (1) · Canadian Cancer Trials Group (1)
Often tested with
Tested in the same studies.
Oleclumab (6) · Durvalumab (5) · Ceralasertib (1) · Savolitinib (1) · Afatinib (1) · Palbociclib (1) · Niraparib (1) · Ragifilimab (1)
Studies
Open first, then newest update. How each study uses monalizumab is read from its arms, and is right about nine times in ten.
Testing it · 18
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Written as Monalizumab
- A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder CancerRecruitingPhase 2John SfakianosNCT06503614Written as Monalizumab
- The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2Not yet recruitingPhase 2Montefiore Medical CenterNCT07146230Written as Monalizumab
- Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical TransplantationRecruitingPhase 2Istituto Clinico HumanitasNCT06892223Written as Monalizumab (anti-NKG2A monoclonal antibody)
- Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerActive, not recruitingPhase 3AstraZenecaNCT04590963Written as Monalizumab
- A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerActive, not recruitingPhase 3AstraZenecaNCT05221840Written as Monalizumab
- Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 TrialCompletedPhase 1National Cancer Institute (NCI)NCT03801902Written as Monalizumab
- Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trialCompletedPhase 2The Netherlands Cancer InstituteNCT04307329Written as Monalizumab
- Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCCompletedPhase 2MedImmune LLCNCT03822351Written as Durvalumab + Monalizumab
- Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingPhase 2Assistance Publique Hopitaux De MarseilleNCT03833440Written as Monalizumab (IPH2201)
- Biomarker-based Study in R/M SCCHNActive, not recruitingPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT03088059Written as IPH2201
- A Dose-Ranging Study of IPH2201 in Patients With Gynecologic MalignanciesCompletedPhase 1Canadian Cancer Trials GroupNCT02459301Written as IPH2201
- Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 InfectionCompletedPhase 2Centre Leon BerardNCT04333914Written as Monalizumab
- Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLLTerminatedPhase 1/2Innate PharmaNCT02557516Written as monalizumab
- Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell TransplantationStatus unknownPhase 1Institut Paoli-CalmettesNCT02921685Written as Monalizumab
- Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CAWithdrawnPhase 1/2Jules Bordet InstituteNCT03307941Written as Monalizumab
- Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral CavityTerminatedPhase 1/2Innate PharmaNCT02331875Written as IPH2201
- Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid ArthritisCompletedPhase 1Innate PharmaNCT01370902Written as NNC 0141-0000-0100
Given in every arm · 5 — monalizumab is usual care beside what is tested
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerRecruitingPhase 2Hirva MamdaniNCT05903092Written as Monalizumab
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyRecruitingPhase 2SWOG Cancer Research NetworkNCT06769126Written as Monalizumab
- A Study of Durvalumab (MEDI4736) and Monalizumab in Solid TumorsActive, not recruitingPhase 1/2MedImmune LLCNCT02671435Written as Monalizumab
- Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedPhase 1/2Innate PharmaNCT02643550Written as Monalizumab
- Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerCompletedPhase 2MedImmune LLCNCT03794544Written as Monalizumab
Codes
What other systems call monalizumab · ClinicalTrials.gg INT001388
- MeSH (NLM) C000709515monalizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3ZXZ2V0588MONALIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q27929456monalizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C120208MonalizumabOne source FDA
- DrugBank DB12824One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000709515 | monalizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3ZXZ2V0588 | MONALIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27929456 | monalizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C120208 | Monalizumab | One source FDA |
| DrugBank | DB12824 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.